Business Context and Reporting Period
This Form 8-K was filed by Nephros, Inc. on August 15, 2016. The report details a regulatory update regarding the Company's Special 510(k) submissions for its 10" PathoGuard and 10" EndoPur filters.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory progress and forward-looking operational expectations.
Material Changes and Operational Updates
- FDA Teleconference: On August 15, 2016, the Company held a teleconference with FDA staff from the Infection Control Devices Branch and Renal Devices Branch.
- Submission Status: The Company now understands the additional testing and information required to complete the submission package for the PathoGuard and EndoPur filters.
- Timeline: The Company expects to complete additional testing and submit the required information before the end of October 2016.
- Commercial Launch: Subject to FDA clearance, commercial sales are expected to begin before the end of 2016.
Guidance, Outlook, and Risks
Cash Flow Outlook: The timing of commercial sales may delay the Company's achievement of positive cash flow until early in the first quarter of fiscal 2017.
Risks and Uncertainties: The filing includes standard forward-looking statement disclaimers. Key risks include potential delays in the regulatory approval process, changes in business or economic conditions, availability of capital, dependence on third-party manufacturers, regulatory reforms, and uncertainties in litigation.
Investor Verification Checklist
- Confirm the completion of additional testing and submission of information by the end of October 2016.
- Monitor the FDA clearance decision timeline for the PathoGuard and EndoPur filters.
- Verify the actual start date of commercial sales relative to the end of 2016 target.
- Track cash flow status to determine if the shift to positive cash flow occurs in early fiscal 2017 as projected.